LEO Pharma's Real-World Tralokinumab Data Bolsters AD Treatment Portfolio

Event summary

  • LEO Pharma presented 12-month real-world data from the TRACE study of tralokinumab at the 2026 AAD Annual Meeting.
  • The TRACE study, an international, non-interventional study, included 824 adult patients with atopic dermatitis.
  • Post-hoc analyses showed a marked decrease in H&F involvement (46.3% to 31.6%) and 80.4% of patients with skin of color achieved disease control at 12 months.
  • 91% of patients achieved at least one moderate treatment target after 12 months of tralokinumab.

The big picture

The presentation of this real-world data underscores LEO Pharma's strategy of leveraging post-market studies to expand the utility and acceptance of tralokinumab. This approach is increasingly common in biopharmaceuticals, as payers and clinicians demand evidence beyond clinical trials. The focus on specific subgroups like those with H&F involvement and skin of color highlights a targeted commercialization strategy aimed at addressing unmet needs within the broader atopic dermatitis patient population, a market estimated to be worth billions annually.

What we're watching

Market Adoption
How the positive real-world data will impact tralokinumab's market share and adoption rates, particularly within the competitive landscape of atopic dermatitis treatments, remains to be seen.
Subgroup Expansion
Whether LEO Pharma will continue to pursue and publish data on additional patient subgroups beyond H&F involvement and skin of color to further broaden the drug's appeal and label.
Regulatory Scrutiny
The FDA's assessment of these real-world data and its potential impact on the drug's labeling and marketing authorization will be a key factor in its long-term commercial success.

Related topics

Pharmaceuticals